KRAS and non-small cell lung carcinoma: Krascendo-170 Lung (NCT05789082) is another ongoing phase Ib/II study evaluating the safety and activity of the combination of divarasib and pembrolizumab with other anticancer therapies in patients with previously untreated, advanced or metastatic KRAS G12C-positive NSCLC [61].